4.7.2 Traditional Childhood Vaccine Safety Concerns

Reference to the Original NCI Report

The Inquiry into the Appropriateness and Efficacy of the COVID-19 Response in Canada (November 28, 2023) primarily addressed concerns regarding COVID-19 vaccines but also identified broader systemic issues in vaccine safety. Testimonies from the NCI Vancouver Hearings expanded the discussion to include traditional childhood vaccines, focusing on safety protocols, adverse event reporting systems, and the cumulative effects of increasingly complex vaccine schedules.

Introduction

The Vancouver NCI hearings brought renewed attention to the safety of traditional childhood vaccines, a topic that has long been overshadowed by debates surrounding newer vaccines, such as those developed in response to the COVID-19 event. While the original NCI report primarily focused on issues related to COVID-19 vaccines, testimonies from experts and advocates at the NCI Vancouver Hearings broadened the conversation to encompass systemic challenges in the evaluation, monitoring, and implementation of childhood immunization programs.

Prominent experts, including Dr. Paul Thomas, Dr. Byram Bridle, Dr. Jessica Rose, Dr. Michelle Perro, and Dr. Stephen Malthouse, raised significant concerns about the current state of vaccine safety protocols. Their testimonies illuminated critical gaps, such as insufficient safety testing, the systemic underreporting of adverse events, and the failure to adequately assess the cumulative risks of vaccine adjuvants and contaminants like aluminum and glyphosate. Witnesses emphasized that these shortcomings not only undermine vaccine safety but also erode public trust in vaccination programs.

A central theme of the testimonies was the lack of rigorous placebo controlled trials to evaluate the long-term effects of traditional childhood vaccines. Witnesses explained that many vaccines are tested against older vaccines or an adjuvant rather than inert placebos, a practice that obscures potential risks and fails to provide a clear understanding of safety profiles. This issue is compounded by the systemic underreporting of adverse events through monitoring systems like VAERS, which capture only a fraction of vaccine related injuries. Experts highlighted how this underreporting distorts public health data and limits the ability to identify and address potential safety concerns.

The testimonies also shed light on the cumulative risks associated with expanded vaccination schedules. Witnesses expressed concern that the administration of multiple vaccines within short time-frames places an unacknowledged burden on children’s developing immune and neurological systems. Adjuvants like aluminum, used to enhance immune responses, were flagged as potential contributors to neuro-developmental disorders, while glyphosate contamination was linked to disruptions in the gut-brain-axis, immune function, and overall health.

Additionally, no studies have been conducted on the combined effects of these vaccines, even though they are now administered in groups of three to four at a time.

Beyond technical critiques, witnesses like Dr. Malthouse and Dr. Thomas emphasized the ethical dimensions of vaccine safety, particularly the importance of informed consent and parental authority. They argued that current policies often marginalize parents, undermining their ability to make decisions in the best interest of their children. Transparency in vaccine safety evaluations and regulatory processes was identified as a crucial step toward rebuilding public trust and fostering collaborative decision-making.

This section synthesizes the insights and concerns raised by witnesses, providing a comprehensive examination of traditional childhood vaccine safety. Their testimonies underscore the pressing need for systemic reforms, including more rigorous safety evaluations, improved adverse event monitoring, and policies that prioritize transparency and individual choice. By addressing these critical issues, public health authorities can better ensure the safety and well-being of children, while restoring confidence in vaccination programs.

Discussion of Witness Testimonies

Dr. Paul Thomas

Overview of Testimony

Dr. Paul Thomas, a board certified paediatrician and leading advocate for informed vaccine choice, presented evidence-based testimony on the health effects of traditional childhood vaccines. Drawing from his clinical experience and research, Dr. Thomas highlighted significant disparities in health outcomes between vaccinated and unvaccinated children. His testimony raised critical concerns about vaccine safety testing, the use of aluminum adjuvants, underreporting of adverse events, and the erosion of informed consent and parental rights.

According to Dr. Thomas:

• 54% of US children are “chronically ill”

• 13% require special education

• 16% have a developmental disorder

• 11% have ADHD

• 1 in 35 have autism

• Millions have asthma and eczema

• 1500 new cases of cancer in US children are reported annually

• Infant mortality in the US is the highest of any high income country

• Autism was reported in 1 in 10,000 children in 1970 and was 1 in 35 in 2020.

In 2020 a review of Dr Thomas’ entire paediatric practise over a decade was subject to a published peer review article.

In his practise there were 561 unvaccinated children and 2763 variably vaccinated, mostly with his “vaccine friendly” protocol. The cumulative number of office visits over the ten year period was reported, separated by vaccinated and unvaccinated children. The results were as follows:

                                     Vaccinated  Unvaccinated

Asthma                               350                  50

Allergic rhinitis                 400                  50

Urticaria and Eczema        680                 180

Dermatitis                          750                  500

Behavioural problems       320                   60

ADHD                               160                   0

Anaemia                            1000                150

Sinusitis                             110                   20

Respiratory infections      5500               1500

Otitis media                      3100                1100

Conjunctivitis                    1000              400

Gastroenteritis                    700               130

Other infections                  2000            700

Key Points from Testimony

• Health Outcomes in Vaccinated vs. Unvaccinated Children:

• Shared findings from his peer-reviewed study, which revealed lower rates of chronic conditions such as asthma, ADHD, and autism in unvaccinated children compared to their vaccinated peers.

• Highlighted that vaccinated children showed higher incidences of eczema, developmental delays, and autoimmune disorders.

• Discussed the improved health trajectories of children following his modified vaccine schedule, which spaces out vaccines and reduces exposure to adjuvants and preservatives.

• Dr. Thomas originally promoted a modified vaccine schedule in 2016 known as the "Vaccine-Friendly Plan." Since then, based on research and clinical data from his practice, he has moved away from that plan and now emphasizes that unvaccinated children appear to be the healthiest group overall.

• Aluminum Adjuvants and Neurotoxicity:

• Criticized the use of aluminum as a vaccine adjuvant, emphasizing its neurotoxic properties and potential harm to developing brains.

• Cited research linking aluminum exposure to neuro-developmental disorders such as autism, especially in infants with immature detoxification systems.

• Highlighted that the cumulative aluminum doses from the standard vaccine schedule often exceed safety thresholds established by regulatory agencies like the FDA.

• Adverse Event Reporting Gaps:

• Identified systemic flaws in vaccine safety monitoring systems, such as VAERS, noting that they capture only 1–2% of actual vaccine-related injuries.

• Emphasized that the underreporting of adverse events distorts public perception of vaccine safety and hinders efforts to identify and mitigate risks.

• Raised concerns about the lack of mechanisms to track long-term adverse effects, leaving critical gaps in safety evaluations.

• Informed Consent and Parental Rights:

• Advocated for transparent and accessible communication of vaccine risks and benefits to empower parents in making informed decisions.

• Criticized policies and practices that pressure or coerce parents into following the standard vaccine schedule without considering individual health needs.

• Emphasized the importance of respecting parental authority and the right to choose what is best for their children’s health.

• Call for Individualized Vaccine Approaches:

• Argued that a "one-size-fits-all" approach to childhood vaccination ignores the unique health needs of individual children, increasing the risk of adverse outcomes.

• Advocates for informed consent and careful evaluation of vaccine risks, emphasizing that unvaccinated children in his practice were the healthiest. While he previously supported personalized vaccine schedules, his more recent findings have led him to question the safety and benefit of routine childhood vaccination altogether.

Dr. Thomas’s testimony highlighted systemic deficiencies in traditional vaccine safety protocols, including inadequate safety testing, gaps in adverse event reporting, and reliance on neurotoxic adjuvants like aluminum.

Dr. Byram Bridle

Overview of Testimony

Dr. Byram Bridle, a virologist and vaccinologist with extensive experience in vaccine development and safety research, provided testimony critiquing the current oversight and evaluation processes for traditional childhood vaccines. His testimony focused on the inadequacy of safety testing, the risks associated with aluminum adjuvants, and the bio-distribution of vaccine components. Drawing on scientific studies and his expertise, Dr. Bridle highlighted systemic flaws in vaccine safety protocols and called for reforms to address these critical issues.

Key Points from Testimony

• Insufficient Safety Testing:

• Criticized the lack of long-term, placebo-controlled trials using inert substances, noting that such trials are essential to identify potential risks and long-term health outcomes.

• Explained that vaccines are often tested against older vaccines and adjuvants instead of true placebos, obscuring safety concerns and preventing a clear assessment of their risk profiles.

• There are no studies have been conducted on the combined effects of these vaccines, even though they are now administered in groups of three to four at a time.

• Flaws in Regulatory Oversight:

• Highlighted selective reporting practices by health agencies, which often fail to provide the public with a comprehensive understanding of vaccine safety.

• Argued that regulatory bodies do not adequately enforce protocols to ensure vaccines undergo independent and unbiased safety evaluations.

• Aluminum Adjuvants and Neurotoxicity:

• Raised concerns about the widespread use of aluminum as a vaccine adjuvant, emphasizing its neurotoxic properties and potential to cause long-term harm.

• Cited studies showing that aluminum can accumulate in the brain and other organs, leading to neuroinflammation and contributing to conditions such as autism, ADHD, and other developmental disorders.

• Pointed out that the cumulative aluminum exposure from multiple vaccines often exceeds established safety thresholds, particularly for young children with underdeveloped detoxification systems.

• Bio-distribution Concerns:

• Discussed evidence showing that vaccine components, including adjuvants like aluminum, do not remain localized at the injection site as previously assumed but travel to various organs throughout the body.

• Warned that this systemic spread of vaccine components could disrupt neurological and immune systems, leading to unintended health consequences.

• Cumulative Risk Assessment:

• Emphasized the need to evaluate the combined effects of administering multiple vaccines within short timeframe and the administration of combination vaccines, particularly in young children who are most vulnerable to toxic exposures. There are no studies conducted on the combined effects of these vaccines, even though they are now administered in groups of three to four at a time.

• Argued that the current vaccination schedules fail to account for the cumulative impact of adjuvants, preservatives, and other components on overall health and development.

• Call for Reforms:

• Advocated for stricter safety standards and independent oversight in vaccine development to ensure unbiased and transparent evaluations.

• Urged regulatory agencies to prioritize public health over industry interests by enforcing rigorous safety protocols and providing accurate data on vaccine risks.

Dr. Bridle’s testimony underscored the critical need for comprehensive reforms in traditional vaccine safety protocols. By addressing gaps in safety testing, regulatory oversight, and cumulative risk assessment, his insights highlighted the importance of establishing higher safety standards to protect children’s health and restore public trust in vaccination programs.

Dr. Jessica Rose

Overview of Testimony

Dr. Jessica Rose, a computational biologist and expert in vaccine adverse event data analysis, provided testimony that focused on systemic weaknesses in vaccine safety monitoring and the potential risks associated with vaccine components and contamination. Drawing from her extensive experience analyzing data from the Vaccine Adverse Event Reporting System (VAERS), Dr. Rose highlighted significant underreporting of vaccine related adverse events and raised concerns about the role of aluminum adjuvants and contaminants such as glyphosate and DNA fragments in vaccines.

Dr. Rose’s analysis of VAERS data:

VAERS (Vaccine Adverse Events Database) is a US program for vaccine safety monitoring managed by the Centres for disease Control (CDC) and Food and Drug Administration (FDA) though the database is open entries from countries other than the US.

Reported adverse events from vaccines averaged approximately 39,000 per year up to the introduction of the COVID-19 mRNA vaccines. In the year following COVID-19 vaccine roll-out, reported adverse reactions rose to 753,047.

Deaths reported to VAERS in the decade prior to the mRNA vaccine introduction were approximately 150 per year. In the year following the introduction of the COVID-19 injections, this rose to 10,596.

It is estimated that only 1-2% of adverse effects are reported to the VAERS database, meaning the actual numbers are likely much higher, potentially significantly higher. The reluctance to report may stem from the time-consuming nature of the reporting system, as well as active discouragement from medical regulatory and licensing authorities in many cases.

It is sometimes argued that the large increase in reports is because a very large number of mRNA vaccinations given during the COVID event, but Dr Rose has analyzed the data to compare reported adverse events for COVID-19 vaccines versus the next commonest vaccine given, the influenza vaccine, normalized by dose.

• Adverse Events (AES) reported per 1,000,000 doses of influenza vaccine is 55

• AES reported per 1,000,000 doses of COVID-19 vaccine is 1378, a difference of 25x.

• Deaths reported per 1,000,000 influenza vaccinations is 0.3

• Deaths reported per 1,000,000 COVID-19 vaccinations is 21, a difference of 70x.

• Cancers reported per 1,000,000 influenza vaccinations is 0.3

• Cancers reported per 1,000,000 COVID-19 vaccinations is 10, a difference of 33x.

In addition, the number of cancers reported since 2020 has risen each year since the introduction of the COVID-19 vaccines and shows no evidence of falling.

There are increasing anecdotal reports of late stage cancers in younger patients, though the data are not conclusive.

Dr. Rose’s Analysis of VAERS Data in Children 0-17

Although healthy children face virtually no risk of dying from COVID-19, and are not significant spreaders of the virus, vaccination for this age group has still been aggressively promoted.

VAERS data show a significant increase in adverse event (AE) reports since COVID-19 injections introduction, especially in the 12-17 age group, with a total of 43,743.

14% of these AES are considered “serious”, meaning the child had to have time off school, was hospitalized, or died.

A total of 200 deaths have been reported, with 58 of these deaths occurring within 24 hours of injection.

An analysis of Canadian data revealed 146 adverse events (AES) reported in children aged 0 to 17. Of these, 55% were classified as serious, and there were 3 reported deaths.

These data far exceed the CDC’s normal recall criteria for newly introduced vaccines, but no action has been taken.

Key Points from Testimony

• Adverse Event Reporting in VAERS:

• Pointed out that VAERS, the primary system for tracking vaccine-related adverse events, captures less than 1–2% of actual incidents, leading to a distorted understanding of vaccine safety.

• Cited data showing high rates of adverse events linked to aluminum containing vaccines, particularly in young children, including developmental delays, neurological disorders, and other chronic health issues.

• Criticized the reliance on passive reporting systems like VAERS, which depend on individuals to voluntarily report adverse events, resulting in substantial data gaps.

• Aluminum Adjuvants and Neuroinflammation:

• Highlighted the neurotoxic properties of aluminum, commonly used as an adjuvant to enhance immune responses in vaccines.

• Discussed research linking aluminum exposure to neuroinflammation, which may contribute to developmental and behavioural disorders such as autism and ADHD.

• Raised concerns about the cumulative effects of aluminum from multiple vaccines administered during early childhood, when detoxification systems are still underdeveloped.

• Vaccine Contamination:

• Dr. Jessica Rose presented findings regarding contaminants in COVID-19 vaccines, including residual DNA fragments resulting from the use of bacterial plasmids in the manufacturing process. She stated that these DNA fragments were introduced when E. coli was used to produce spike protein-encoding plasmids for large-scale vaccine production. Dr. Rose further testified that compendia standards for biological product safety and quality were not adhered to.

• Warned that these contaminants could have unknown long-term effects on children’s health, including disruptions to immune function and increased risks of autoimmune disorders.

• Criticized inadequate oversight in vaccine manufacturing processes, calling for stricter regulations and independent monitoring to prevent contamination.

• Call for Systemic Reforms in Monitoring and Manufacturing:

• Advocated for the overhaul of vaccine safety monitoring systems to ensure comprehensive data collection and analysis of adverse events.

• Called for independent investigations into the long-term health effects of vaccine components and contaminants.

• Emphasized the need for transparency and accountability in vaccine manufacturing and safety evaluations to rebuild public trust.

Dr. Rose’s testimony highlighted critical flaws in vaccine safety monitoring and manufacturing, underscoring the urgent need for systemic reforms to protect children’s health. By emphasizing the risks posed by aluminum adjuvants, underreported adverse events, and vaccine contamination, she made a compelling case for improving safety standards and fostering greater transparency in public health policies.

Dr. Michelle Perro

Overview of Testimony

Dr. Michelle Perro, a paediatrician with over four decades of clinical experience and expertise in environmental health, provided a comprehensive critique of traditional childhood vaccine safety during the Vancouver NCI hearings. Her testimony emphasized the interconnectedness of vaccine components, environmental toxins, microbiome health, and the cumulative impacts of medical interventions on children’s long-term development. Drawing from her clinical practice and research, Dr. Perro identified critical gaps in vaccine safety evaluation and highlighted the need for a holistic, integrative approach to addressing systemic failures.

Key Points from Testimony

• Glyphosate and Microbiome Disruption:

• Highlighted the presence of glyphosate, a widely used herbicide, as a contaminant in vaccines and discussed its adverse effects on the microbiome.

• Explained how glyphosate disrupts the gut-brain-axis by depleting beneficial gut bacteria and promoting harmful strains, such as Clostridia, which can impair serotonin production, a neurotransmitter essential for mood regulation.

• Linked microbiome imbalances caused by glyphosate to neurological and developmental disorders, including autism spectrum disorders, anxiety, and depression.

• Aluminum Adjuvants and Cumulative Toxic Burden:

• Criticized the widespread use of aluminum as a vaccine adjuvant, emphasizing its neurotoxic properties and the lack of research into its long-term effects on children.

• Discussed studies showing that aluminum can cross the blood brain barrier, accumulate in the brain, and contribute to neuroinflammation, which is associated with cognitive and behavioural disorders such as ADHD and autism.

• Warned that current vaccine schedules fail to account for the cumulative toxic burden of multiple vaccine components, including aluminum, administered within short timeframes.

• Cautioned that the administration of combination vaccines has not been studied.

• Environmental and Dietary Factors in Vaccine Safety:

• Addressed the synergistic effects of environmental toxins, such as pesticides and chemicals, with vaccine components, amplifying risks to children’s health.

• Highlighted how poor diets, rich in processed food and low in essential nutrients, further compromise the gut-brain-axis and exacerbate vaccine-related health challenges.

• Call for Integrative Research and Transparency:

• Advocated for independent, integrative research into the cumulative risks posed by vaccine schedules, environmental toxins, and dietary factors.

• Criticized the lack of transparency in vaccine safety evaluations and called for greater accountability in addressing these systemic issues.

• The Need for Holistic Solutions:

• Emphasized the importance of adopting holistic approaches to vaccine safety that consider environmental, dietary, and medical factors in tandem.

• Urged policymakers to prioritize strategies that support microbiome health, reduce toxic exposures, and educate families on maintaining overall health and resilience.

Dr. Perro’s testimony offered a holistic perspective on the intersection of environmental health and vaccine safety. By exposing the systemic failures in evaluating cumulative risks and highlighting the role of the microbiome in children’s health, she underscored the urgent need for comprehensive reforms in vaccine protocols and public health policies to safeguard children’s well-being.

Dr. Stephen Malthouse

Overview of Testimony

Dr. Stephen Malthouse, a family physician with extensive clinical experience, critiqued the safety evaluation and oversight of traditional childhood vaccines. He raised concerns about the lack of rigorous safety testing, systemic underreporting of adverse events, and the influence of pharmaceutical companies on vaccine research and regulatory processes.

Key Points from Testimony

• Insufficient Safety Testing:

• Highlighted the absence of long-term, placebo controlled trials using inert substances, which obscures the true safety profiles of traditional childhood vaccines.

• Emphasized the need for independent studies to assess the cumulative risks of vaccine components over time.

• Adverse Event Reporting Gaps:

• Criticized current adverse event tracking systems for failing to capture the full scope of vaccine-related injuries, pointing out that many events go unreported.

• Stressed the need for improved monitoring systems to ensure accurate data collection and analysis.

• Concerns about Vaccine Adjuvants:

• Highlighted the neurotoxic properties of aluminum adjuvants commonly used in vaccines and their potential link to chronic illnesses such as autism and ADHD.

• Warned about the long-term health implications of cumulative aluminum exposure in children.

• Pharmaceutical Influence on Public Health Policies:

• Expressed concerns about the influence of pharmaceutical companies on vaccine research, regulatory oversight, and public health recommendations.

• Called for greater transparency and independence in vaccine development and approval processes to restore public trust.

• Parental Authority and Informed Consent:

• Criticized policies that undermine parental authority by allowing vaccine administration without informed parental consent.

• Advocated for empowering parents with clear, unbiased information to make informed decisions about their children’s health.

Dr. Malthouse’s testimony highlighted significant flaws in traditional vaccine safety protocols and emphasized the need for systemic reforms, including stricter safety standards, improved adverse event tracking, and enhanced transparency in public health decision-making. His insights underscored the importance of empowering families to make informed choices in the best interest of their children.

Kathy Stack

Overview of Testimony

Kathy Stack testified about her experience as a mother of a child with Down syndrome and the health complications he faced following early childhood vaccinations. As an intensive care nurse at the time, she followed standard medical advice but later questioned the impact of vaccines on her son’s health. Her testimony focused on the immediate and long-term effects of vaccination, medical responses, and broader concerns about vaccine safety.

Key Points

• Early Childhood and Initial Health Status:

• Stack gave birth to her son, in 1989. He was born a healthy 10-pound, 3-ounce baby and was diagnosed with Down syndrome at birth.

• Despite his diagnosis, he met developmental milestones in his early months. She documented his progress, including smiling and reaching for her face.

• Adverse Reaction to Vaccination:

• At three and a half months, she took her son for his first diphtheria, pertussis, and tetanus (DPT) vaccine, following medical recommendations.

• Within hours of receiving the shot, he developed a high fever and became highly irritable.

• She treated him with Tylenol and put him to bed but did not initially suspect a severe reaction.

• Medical Complications and Concerns:

• Stack’s concerns about vaccine safety grew as her son’s health issues persisted.

• She later questioned whether the vaccine may have contributed to developmental and health challenges beyond his Down syndrome diagnosis.

• Her experience led her to reevaluate her trust in standard medical practices regarding childhood immunization.

Kathy Stack’s testimony highlights concerns about vaccine safety, particularly for children with pre-existing conditions such as Down syndrome. As both a mother and a healthcare professional, her perspective illustrates the challenges parents face in making informed medical decisions. Her experience underscores the need for greater transparency and thorough investigation of adverse reactions to childhood vaccinations.

Discussion and Analysis of Issues Raised by the Witnesses

The Vancouver NCI hearings exposed systemic failures in the safety evaluation, monitoring, and regulatory oversight of traditional childhood vaccines. Witnesses consistently raised concerns about insufficient safety testing, significant underreporting of adverse events, and the cumulative risks posed by adjuvants and contaminants. These issues highlight critical gaps in the existing framework for ensuring vaccine safety and public trust.

Insufficient Safety Testing

Witnesses, including Dr. Stephen Malthouse and Dr. Byram Bridle, emphasized the lack of long-term, placebo controlled trials using inert substances to assess vaccine safety. Current practices often compare new vaccines to older ones that may already carry risks, obscuring the ability to identify long-term or cumulative health effects.

• Dr. Malthouse criticized the absence of independent studies assessing the cumulative risks of vaccine components over time.

• Dr. Bridle explained that the reliance on flawed safety evaluation protocols prevents a clear understanding of the potential neurological and developmental impacts of vaccines, particularly for young children.

Underreporting of Adverse Events

Systemic underreporting in vaccine monitoring systems, such as VAERS, was a recurring theme. Dr. Jessica Rose highlighted that VAERS captures less than 1–2% of vaccine-related adverse events, creating significant data gaps.

• This underreporting distorts the safety profile of vaccines and hinders efforts to address potential risks.

• Dr. Malthouse called for improved monitoring systems and mandatory reporting by healthcare providers to ensure accurate tracking of adverse events.

Cumulative Risks of Vaccine Adjuvants and Contaminants

The testimonies of Dr. Thomas, Dr. Perro, and Dr. Malthouse raised concerns about the cumulative risks posed by vaccine adjuvants, such as aluminum, and contaminants, such as glyphosate.

• Dr. Thomas highlighted the neurotoxic properties of aluminum and its links to developmental disorders, including autism and ADHD.

• Dr. Perro explained how glyphosate contamination disrupts the microbiome and the gut-brain-axis, contributing to neurological and immune dysfunction.

• Dr. Malthouse emphasized the need for a comprehensive evaluation of the cumulative toxic burden resulting from multiple vaccines administered in short timeframes, and the administration of combination vaccines.

Erosion of Trust and Parental Authority

Witnesses criticized the lack of transparency in vaccine policy development and the exclusion of parental voices.

• Dr. Malthouse and Dr. Thomas emphasized the importance of respecting parental authority and providing clear, unbiased information to enable informed consent.

Physicians Lack Substantial Knowledge Concerning Vaccines

Dr. Paul Thomas and Dr. Stephen Malthouse stated that physicians generally lack substantial knowledge about vaccines and vaccine combinations.

Dr. Paul Thomas:

• He emphasized that physicians are not adequately educated on vaccine safety, especially regarding cumulative risks and aluminum adjuvants.

• He explained that vaccines are not tested against inert placebos, making it difficult even for doctors to evaluate safety claims accurately.

• In his updated position, he explicitly stated that after more research, he no longer recommends his former “Vaccine-Friendly Plan,” acknowledging that the data since 2016 shows even that reduced schedule has risks.

Dr. Stephen Malthouse:

• He was even more direct, stating that doctors are not given proper education on vaccines, and are instead “indoctrinated with propaganda”.

• Dr. Malthouse criticized the practice whereby physicians are often not involved in administering vaccines, resulting in their exclusion from the active decision-making process. He expressed concern that, particularly when public health authorities oversee vaccination programs in schools, medical professionals are sidelined from individualized patient care and consent discussions.

• He also noted that doctors are not in a position to explain vaccine risks and alternatives to children because they themselves don’t understand the vaccines well enough.

Conclusion

The testimonies from the Vancouver NCI hearings revealed significant systemic shortcomings in the safety evaluation and oversight of traditional childhood vaccines. Experts identified critical issues, including insufficient safety testing, significant underreporting of adverse events, and the cumulative risks posed by aluminum adjuvants and contaminants like glyphosate. Additionally, witnesses highlighted the erosion of parental trust due to a lack of transparency and the exclusion of parents from decision-making processes.

It is essential that healthcare providers receive comprehensive, evidence-based education on the full spectrum of vaccine-related information, including both the known benefits and risks, as well as the unknowns resulting from insufficient long-term safety studies and limited research on combined vaccine schedules. This education must also address concerns related to potentially harmful components, such as aluminum and other adjuvants, whose cumulative effects remain inadequately understood.

Ensuring that physicians are properly informed will enable them to engage in transparent, honest communication with parents. In turn, this will support truly informed consent, allowing parents to make decisions that reflect a balanced understanding of both the proven and potential risks and benefits associated with vaccination.

These findings underscore the need for comprehensive reforms to ensure that childhood vaccine policies prioritize the safety, health, and well-being of children. By addressing systemic flaws, and fostering open dialogue with families, public health authorities can rebuild confidence in vaccination programs and better protect the youngest members of society.

Recommendations

1. Improve Safety Testing:

• Mandate long-term, placebo-controlled trials using inert substances for all vaccines.

• Require independent research to assess the cumulative risks of vaccine components, including adjuvants, preservatives and the safety of combination vaccines.

• Until comprehensive safety testing is completed, a precautionary approach should be adopted. This includes limiting the use of certain vaccines in children, enhancing adverse event monitoring, and ensuring that parents receive full disclosure of both known and unknown risks to support informed decision-making.

2. Enhance Monitoring Systems:

• Revamp adverse event reporting systems like VAERS to ensure comprehensive and accurate tracking.

• Implement mandatory reporting requirements for healthcare providers to capture vaccine-related injuries effectively.

3. Reassess Adjuvant and Contaminant Safety:

• Conduct independent studies into the long-term neurological and developmental effects of aluminum adjuvants.

• Eliminate glyphosate contamination and harmful substances, such as aluminum, mercury and others from vaccines.

4. Enforce True Informed Consent and Parental Involvement:

• It is essential that healthcare providers receive comprehensive, evidence-based education on the full spectrum of vaccine-related information, including both the known benefits and risks, as well as the unknowns resulting from insufficient long-term safety studies and limited research on combined vaccine schedules. This education must also address concerns related to potentially harmful components, such as aluminum and other adjuvants, whose cumulative effects remain inadequately understood.

• Provide parents with clear, evidence-based information about vaccine risks and benefits.

• Empower parents to make informed decisions regarding the vaccination of their children based on individual health needs rather than standardized schedules.

• Ensure that vaccinations are no longer administered in schools to uphold parental authority and to prevent children from experiencing undue pressure, whether from school authority figures or from peer influence among classmates.

5. Strengthen Regulatory Oversight:

• Ensure independent oversight of vaccine safety evaluations to eliminate conflicts of interest.

• Increase transparency in clinical trial data, regulatory processes, and public health communications to restore trust.

• Hold pharmaceutical companies accountable for any harms their products cause.

6. Address Cumulative Risks:

• Develop guidelines to evaluate the cumulative effects of multiple vaccines administered within short time-frames.

• Prioritize research into the combined impacts of combination vaccines, environmental toxins, dietary factors, and vaccine components on children’s health.

7. Rebuild Trust and Accountability:

• Foster open dialogue with families and include parents and child development experts in policy-making processes.

• Promote ethical oversight to ensure vaccine policies prioritize the well-being of children over industry interests.

By implementing these recommendations, Canada can establish a safer, more transparent, and family-centred framework for childhood immunization. These changes are critical to addressing public concerns and protecting the health and future of Canadian children.